Arcellx (ACLX) Income from Continuing Operations (2021 - 2025)
Arcellx (ACLX) recorded quarterly Income from Continuing Operations of 58112000.0 in Q4 2025, down 4.18% quarter-over-quarter from 55781000.0 in Q3 2025, and down 23.43% on a YoY basis from 75893788.4 in Q4 2024.
Arcellx (ACLX) Income from Continuing Operations (2021 - 2025) Analysis & Trends
Arcellx's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 58112000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 23.43% year-over-year to 58112000.0; the TTM figure through Dec 2025 stood at 228934000.0 (down 113.39% YoY), while the FY2025 annual figure was 228934000.0, down 113.26% from the prior year.
- Income from Continuing Operations was 58112000.0 for Q4 2025 at Arcellx, down from 55781000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19844000.0 in Q4 2023 to a low of 92874000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 33030250.0 across 5 years, with a median of 27252500.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations soared 150.89% in 2023, then tumbled 765.1% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 20698000.0 in 2021, then plunged by 88.39% to 38992000.0 in 2022, then jumped by 150.89% to 19844000.0 in 2023, then tumbled by 337.26% to 47081000.0 in 2024, then fell by 23.43% to 58112000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 58112000.0 (Q4 2025), 55781000.0 (Q3 2025), and 52771000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -58.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58.11 Mn |
| Sep 30, 2025 | -55.78 Mn |
| Jun 30, 2025 | -52.77 Mn |
| Mar 31, 2025 | -62.27 Mn |
| Dec 31, 2024 | -47.08 Mn |
| Sep 30, 2024 | -25.84 Mn |
| Jun 30, 2024 | -27.16 Mn |
| Mar 31, 2024 | -7.20 Mn |
| Dec 31, 2023 | 19.84 Mn |
| Sep 30, 2023 | -39.34 Mn |
| Jun 30, 2023 | -23.85 Mn |
| Mar 31, 2023 | -27.34 Mn |
| Dec 31, 2022 | -38.99 Mn |
| Sep 30, 2022 | -92.87 Mn |
| Jun 30, 2022 | -30.77 Mn |
| Mar 31, 2022 | -26.04 Mn |
| Dec 31, 2021 | -20.70 Mn |
| Sep 30, 2021 | -17.11 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |